University of Limerick Institutional Repository

Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates

DSpace Repository

Show simple item record Ruozi, Barbara Belletti, Daniela Pederzoli, Francesca Masoni, Martina Keller, Johannes Ballestrazzi, Antonio Vandelli, Maria Angela Tosi, Giovanni Grabrucker, Andreas M. 2017-07-26T13:48:47Z 2017
dc.description peer-reviewed en_US
dc.description.abstract . The formation of extracellular aggregates built up by deposits of β-amyloid (Aβ) is a hallmark of Alzheimer’s disease (AD). Curcumin has been reported to display anti-amyloidogenic activity, not only by inhibiting the formation of new Aβ aggregates, but also by disaggregating existing ones. However, the uptake of Curcumin into the brain is severely restricted by its low ability to cross the blood-brain barrier (BBB). Therefore, novel strategies for a targeted delivery of Curcumin into the brain are highly desired. Here, we encapsulated Curcumin as active ingredient in PLGA (polylactide-co-glycolic-acid) nanoparticles (NPs), modified with g7 ligand for BBB crossing. We performed in depth analyses of possible toxicity of these NPs, uptake, and, foremost, their ability to influence Aβ pathology in vitro using primary hippocampal cell cultures. Our results show no apparent toxicity of the formulated NPs, but a significant decrease of Aβ aggregates in response to Curcumin loaded NPs. We thus conclude that brain delivery of Curcumin using BBB crossing NPs is a promising future approach in the treatment of AD. en_US
dc.language.iso eng en_US
dc.publisher Elsevier en_US
dc.relation.ispartofseries International Journal of Pharmaceutics;526 (1-2), pp. 413-424
dc.rights This is the author’s version of a work that was accepted for publication in Internatonal Journal of Pharmaceutics.. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Intrnational Journal of Pharmaceutics, 526, (1-2), pp., 413-424, en_US
dc.subject synapse en_US
dc.subject amyloid en_US
dc.subject Alzheimers disease en_US
dc.subject BBB targeting nanoparticles en_US
dc.subject nanotechnology en_US
dc.subject curcumin en_US
dc.title Novel curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US 2017-07-26T13:33:11Z
dc.description.version ACCEPTED
dc.identifier.doi 10.1016/j.ijpharm.2017.05.015
dc.contributor.sponsor UNIMORE en_US
dc.relation.projectid FAR 2014 en_US 2018-06-30
dc.embargo.terms 2018-06-30 en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US
dc.internal.rssid 2710709
dc.internal.copyrightchecked Yes
dc.identifier.journaltitle International Journal Of Pharmaceutics
dc.description.status peer-reviewed

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


My Account